• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Coagulation & Plasma Transfusion

High Titer Convalescent Plasma Does Not Improve Survival of Hospitalized Patients with COVID-19

With few treatment options, more than 500,000 patients with COVID-19 were transfused with convalescent plasma in the United States.  Observational…

May 26, 2021

ABO-incompatible Platelet Transfusions and Platelet Recovery in Patients with Intracerebral Hemorrhage

Historically, standard practice has been to provide ABO-compatible platelets when possible.  However, since hemolysis is rare after single platelet transfusions…

May 18, 2021

Tranexamic Acid To Reduce Blood Loss after Cesarean Delivery

Tranexamic acid is a common antifibrinolytic drug used to prevent blood loss during surgeries and treat heavy menstrual cycles.  Several…

May 5, 2021

Updated Guidance for COVID-19 Convalescent Plasma Use from the FDA and AABB

With a lack of effective treatments for COVID-19, the U.S. FDA issued Emergency Use Authorization to use convalescent plasma to…

February 17, 2021

Early Convalescent Plasma Therapy Helps Prevent Severe COVID-19

COVID-19 convalescent plasma administered late in the course of disease has not shown clear benefits, but some studies suggest that…

January 12, 2021

Cochrane Living Systematic Review: More Data Needed to Determine Efficacy of COVID-19 Convalescent Plasma

Researchers from the Cochrane Library are performing monthly systematic reviews to evaluate the current data on the effectiveness of COVID-19…

October 28, 2020

COVID-19 Convalescent Plasma Provides More than Neutralizing Antibodies

With few drugs to combat SARS-CoV-2 infections and the approval from the U.S. FDA for Emergency Use Authorization of COVID-19…

September 30, 2020

NIH Urges Randomized Controlled Trials for COVID-19 Convalescent Plasma

On September 1, 2020, shortly after the U.S. Food and Drug’s Emergency Use Authorization (EUA) for the use of COVID-19…

September 9, 2020

FDA Issues Emergency Use Authorization for COVID-19 Convalescent Plasma

To increase access to COVID-19 convalescent plasma (CCP) use, President Trump, in conjunction with the U.S. FDA, announced Emergency Use…

August 25, 2020

Convalescent Plasma Is Safe and Likely Efficacious for Patients with COVID-19

There are limited therapeutic options to treat COVID-19, and COVID-19 convalescent plasma (CCP) is currently one of the most common…

August 4, 2020

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Interim pages omitted …
  • Page 9
  • Go to Next Page »

Primary Sidebar

Latest News

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley